INTERVIEW: Goldman's dreams of competitive collaboration as IMI 2 considered
This article was originally published in Scrip
Executive Summary
With around €1.2 billion of the Innovative Medicines Initiative's €2 billion budget already spent financing around 40 projects, executive director Michel Goldman's thoughts are turning to the possibility of an IMI 2. He told Scrip in an exclusive interview that he believes the IMI's successes to date are enough to weigh in favor of another IMI scheme, and set out the case for more clinically-oriented elements for the next phase of IMI.